Some of the negative microbial signatures for GLP-1 RA treatment in T2D patients might be related to diseases
N Engl J Med 381(9):841851 Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Practical Considerations for Starting Combined TRT and GLP-1 Therapy If you are already on stable TRT, adding a GLP-1 medication typically requires no adjustment to testosterone dosing
Some doctors call it reckless
Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties
However, this case lacks a temperature display, making it difficult to determine the exact temperature of your meds